These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 30880359)

  • 1. Relapsed T Cell ALL: Current Approaches and New Directions.
    McMahon CM; Luger SM
    Curr Hematol Malig Rep; 2019 Apr; 14(2):83-93. PubMed ID: 30880359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
    DeAngelo DJ
    Hematol Oncol Clin North Am; 2009 Oct; 23(5):1121-35, vii-viii. PubMed ID: 19825456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
    Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
    J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Frey NV; Luger SM
    Blood; 2015 Jul; 126(5):589-96. PubMed ID: 25966988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia: literature review and own experience.
    Dyakonova YY; Bydanov OI; Popov AM; Olshanskaya YV; Boichenko EG; Aleynikova OV; Maschan MA; Shelikhova LN; Litvinov DV; Khachatryan LA; Ponomareva NI; Fechina LG; Novichkova GA; Pashanov ED; Karachunskiy AI
    Ter Arkh; 2018 Aug; 90(7):38-50. PubMed ID: 30701921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation.
    Gökbuget N; Basara N; Baurmann H; Beck J; Brüggemann M; Diedrich H; Güldenzoph B; Hartung G; Horst HA; Hüttmann A; Kobbe G; Naumann R; Ratei R; Reichle A; Serve H; Stelljes M; Viardot A; Wattad M; Hoelzer D
    Blood; 2011 Sep; 118(13):3504-11. PubMed ID: 21715318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of Relapsed/Refractory Acute Lymphoblastic Leukemia Today and Tomorrow.
    Hrabovský Š; Folber F; Doubek M
    Klin Onkol; 2019; 32(2):90-96. PubMed ID: 30995847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and emerging therapeutic approaches for T-cell acute lymphoblastic leukaemia.
    Pocock R; Farah N; Richardson SE; Mansour MR
    Br J Haematol; 2021 Jul; 194(1):28-43. PubMed ID: 33942287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma.
    Luskin MR; Ganetsky A; Landsburg DJ; Loren AW; Porter DL; Nasta SD; Svoboda J; Luger SM; Frey NV
    Br J Haematol; 2016 Jul; 174(2):332-4. PubMed ID: 26403537
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
    Cohen MH; Johnson JR; Justice R; Pazdur R
    Oncologist; 2008 Jun; 13(6):709-14. PubMed ID: 18586926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis.
    Kathpalia M; Mishra P; Bajpai R; Bhurani D; Agarwal N
    Ann Hematol; 2022 Aug; 101(8):1655-1666. PubMed ID: 35727338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma.
    Candoni A; Lazzarotto D; Petruzzellis G
    Expert Opin Drug Saf; 2021 Jul; 20(7):751-756. PubMed ID: 33866913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Update on Clinical Trials and Potential Therapeutic Strategies in T-Cell Acute Lymphoblastic Leukemia.
    Patel J; Gao X; Wang H
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating adults with acute lymphocytic leukemia: new pharmacotherapy options.
    Thomas X; Le Jeune C
    Expert Opin Pharmacother; 2016 Dec; 17(17):2319-2330. PubMed ID: 27759440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Approaches for the Interim Management of Relapsed/Refractory Acute Lymphocytic Leukemia: A Case-Study Compendium.
    Wang ES; Jabbour EJ; Douer D
    Clin Adv Hematol Oncol; 2016 Mar; 14(3 Suppl 4):1-23. PubMed ID: 27007406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia.
    Lato MW; Przysucha A; Grosman S; Zawitkowska J; Lejman M
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults.
    Ronson A; Tvito A; Rowe JM
    Curr Oncol Rep; 2016 Jun; 18(6):39. PubMed ID: 27207612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia.
    Fulcher J; Berardi P; Christou G; Villeneuve PJA; Bredeson C; Sabloff M
    Leuk Lymphoma; 2021 Sep; 62(9):2295-2297. PubMed ID: 33749497
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review).
    Evangelisti C; Evangelisti C; Chiarini F; Lonetti A; Buontempo F; Bressanin D; Cappellini A; Orsini E; McCubrey JA; Martelli AM
    Int J Oncol; 2014 Sep; 45(3):909-18. PubMed ID: 24968804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.